Proven market need with strong momentum from industry validation and non-dilutive funding. Validated market need through direct engagement with industry leaders.
-
"Need cell therapy manufacturing technologies that are highly scalable
— CMC Lead at Large Pharma
-
"Need high throughput and retrievable encapsulated cell products, need better solutions to immune rejection"
— External Innovation Director at Large Pharma
-
"Need encapsulation technologies that are easily integrated and scalable, need better solutions to immune rejection"
— Translational Engineer at Large Pharma
Non-dilutive Funding and Resources
-
NSF
Innovation Corps
- NIH
-
FLINN
FOUNDATION
-
Advanced Regenerative Manufacturing Institute
BioFabUSA
Backed by leading institutions in innovation, healthcare research, and advanced manufacturing
-
20+
Industry interviews conducted
-
100%
Confirmed need for scalable solutions
-
Multiple
Partnership discussions initiated
What's Next
Large Animal Studies
-
$1.8M Phase II SBIR Award
Recently awarded
Two years of funding for studying cell encapsulation technology in a large animal model
-
University of Miami Partnership
Partnering with University of Miami Diabetes Research Institute
World leader in cure-focused research for diabetes
-
Current Focus
Seeking funding to round out studies with immune tolerance validation
Milestones Achieved
Large Animal Studies
-
NSF Innovation Corps
Completed intensive customer discovery program, validating market need through 20+ industry interviews
-
NIH Phase I SBIR
$300K award for proof-of-concept validation in small animal models
-
NIH Phase II SBIR - $1.8M
Recently awarded for large animal validation studies with University of Miami Diabetes Research Institute
-
Technology License
Secured exclusive license for foundational IP from leading research institution
-
Flinn Foundation Award
Bioscience Entrepreneurship Award recognizing commercial potential
Total Non-Dilutive Funding Secured
$2.6M+
Demonstrates strong institutional confidence in technology and team